Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
The immunopathology of multiple sclerosis: an overview.
Visualization of myelination in GFP-transgenic zebrafish.
Withdrawal of the marketing authorization in the European Union
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
A full genome search in multiple sclerosis.
Intas launches biosimilar version of Rituximab
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Pharmacokinetics of CAMPATH-1H in BMT patients.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion

Pages